Theramex has launched Bijuva® / Bijuve® (1mg oestradiol / 100mg progesterone) across Europe and the UK.
Bijuva® – known as Bijuve® in the UK – is the first and only body-identical hormone therapy treatment (HRT) for oestrogen deficiency symptoms in post-menopausal women with intact uterus and at least 12 months since last menses, which combines oestradiol and progesterone in a single daily oral capsule.
Unlike synthetic hormone products, the oestradiol and progesterone found in Bijuva® / Bijuve® are chemically and biologically identical to the hormones naturally circulating in the woman’s body.
Real-world evidence, recognised by NICE and the British Menopause Society, suggests that use of body‑identical hormones is associated with lower risks compared to synthetic versions.
In particular, the evidence base demonstrates that body-identical hormones have not been shown to increase the risk of venous thromboembolism and are safer forms of HRT with respect to the risk for breast cancer, heart disease, heart attack, and stroke.
The idea of using body identical hormones to replace oestrogens and to protect the endometrium with progesterone appeals to many women. These hormones that many women prefer are now available in a combined single capsule that has been shown to be effective and well-tolerated.
Dr Paula Briggs, incoming Chair of the British Menopause Society, said: “We know women can be concerned about taking hormones and the impact they may have on their health beyond treating menopause symptoms.
“The availability of a body-identical progesterone which is well tolerated and has a lower risk profile than oral synthetic progestogens, combined with oestradiol in a single capsule, is great news for women.
“As a healthcare community we should encourage our patients to reconsider the benefits of newer therapeutic options, allowing them to make informed choices.”
Theramex CEO, Robert Stewart, commented: “For many years menopausal women and their healthcare providers have been seeking an EMA approved body-identical combination therapy.
“The approval of Bijuva® / Bijuve® during Menopause Awareness month represents an important new opportunity for menopausal women suffering from moderate to severe vasomotor symptoms.”
